SillaJen Grabs Jennerex, Inc. for $150 Million
11/26/2013 6:53:02 AM
More...
|
Jennerex, Inc. Announces That Its Phase 2 Study of Pexa-Vec in Second-Line Advanced Liver Cancer Did Not Meet Its Primary Endpoint
9/3/2013 2:08:23 PM
More...
|
Jennerex, Inc. to Present at the 33rd Annual Canaccord Genuity Growth Conference
8/12/2013 6:46:56 AM
More...
|
TRANSGENE (TRGNY) Announces a Follow-on Investment in Jennerex, Inc.
5/28/2013 9:51:16 AM
More...
|
Jennerex, Inc. Completes $21.6 Million Private Placement
5/23/2013 7:30:07 AM
More...
|
Jennerex, Inc. Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer
5/21/2013 11:16:33 AM
More...
|
Jennerex, Inc. Announces Science Translational Medicine Publication Highlighting Pexa-Vec's Ability to Induce Functional Anti-Cancer Immunity in Patients With Diverse Tumor Types
5/16/2013 12:10:12 PM
More...
|
Jennerex, Inc. Granted FDA Orphan Drug Designation for Pexa-Vec in Hepatocellular Carcinoma (HCC)
5/9/2013 11:03:16 AM
More...
|
Jennerex, Inc. Announces Presentation of Data Demonstrating Pexa-Vec's Vascular Targeting Mechanism
4/9/2013 11:41:49 AM
More...
|
Liver Cancer Survival Time Tripled by Virus, Jennerex, Inc. Reveals
2/13/2013 7:22:52 AM
More...
|
|